FIELD: medicine; diagnostics.
SUBSTANCE: present invention relates to diagnostics, namely to a method for estimating the mortality risk of COPD patients for 2 years. Method for estimating the mortality risk of COPD patients for 2 years, where the method involves the steps of: providing a blood sample, serum, plasma, cerebrospinal fluid, urine, saliva, sputum or pleural effusions from said patient; determining in said sample the level of a precursor fragment of at least 12 amino acids length of at least one biomarker, wherein said biomarker is selected from a group consisting of procalcitonin (PCT; SEQ ID NO: 12), PCT 1-116, PCT 2-116, PCT 3-116, mid-regional prodreno-medullin (MR-proADM; SEQ ID NO: 7), a medium region atrial natriuretic peptide (MR-pro-ANP), copectin (SEQ ID NO: 10), with certain boundaries of passing the marker; determining BODE index parameters, then performing correlation of said level of at least one biomarker in combination with said parameters of BODE index, to assess the mortality risk for 2 years of the COPD patients, to this end, assessing the score for the biomarker based on different transmission boundaries; fixing the score in each of the tested BODE index parameters (B and D or B, D and O); scores are summed up in a combined score, where score of 0 to 3 corresponds to a low mortality rate in COPD patients for 2 years, score of 4 to 6 corresponds to an average mortality rate of COPD patients for 2 years, and value of points from 7 to 13 corresponds to high risk of mortality of COPD patients for 2 years.
EFFECT: method described above enables reliable estimating of mortality risk in COPD patients for 2 years.
6 cl, 36 dwg, 1 ex, 6 tbl
